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Abstract
Purpose.  This paper applies the Dynamically Modified Outcomes (DYNAMO) model to
a clinical trial of two chemotherapeutic regimens on global health-related quality of life 
(GHRQL) in hormone-refractory prostate cancer.   Methods.  DYNAMO identifies the 
causal influences operating in a clinical trial and their mediation, moderation, and 
modulation by uncontrolled variables.  Southwest Oncology Group Trial S9916 
randomized assignment to mitoxantrone plus prednisone (M+P) versus docetaxel plus 
estramustine (D+E) treatments.  In this application, we examine baseline-adjusted  
impacts of Worst Pain (McGill Pain Questionnaire) on GHRQL (EORTC Quality of Life 
Questionnaire-C30)at 10 weeks.  Results.   Average treatment levels of Pain did not 
differ, hence the average mediated effect of treatment on GHRQL was zero.  
Nonetheless, M+P reduced the impact (the relational outcome) of Pain on GHRQL by 
54% relative to D+E.  Individual variation in the relational outcome (modulation) was 
of the same magnitude as the average difference between arms. Performance status 
moderated the direct effects of treatment, with D+E more effective in good, but not 
poor, performance strata.    Conclusions.  The DYNAMO approach comprehensively 
accounted for treatment effects.  Rather than a single average effect, there were three 
distinct treatment effects:  one direct effect for each performance status level, and a 
direct effect on the relationship between pain and GHRQL.  
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3Introduction
This paper applies the Dynamically Modified Outcomes (DYNAMO) causal analysis 
approach (Donaldson et al., this issue) to a chemotherapeutic trial targeting health-
related quality of life (HRQL) in hormone-refractory prostate cancer.  The theoretical 
framework for this approach explicates the direct causal effects of an intervention, and 
the mediators, moderators, and modulators that qualify them in the context of a 
clinical trial.  This example extends earlier work, which discussed general latent trait 
analysis of variance models for clinical trials [1], the prominence of individual 
differences in treatment response [2], and the advantages that accrue when symptom 
outcomes are integrated within multivariate longitudinal analysis of general HRQL 
domains [3].  
In this paper we apply the new DYNAMO approach to Southwest Oncology 
Group (SWOG) trial S9916, which compared mitoxantrone plus prednisone and 
docetaxel plus estramustine for men with hormone-refractory prostate cancer (HRPC)
[4].  No conclusive evidence for significant differences in the primary HRQL endpoints
(pain palliation and global HRQL [GHRQL]) was found [5].  Trial design, therapeutic 
results, and HRQL analyses are described below.  
Moinpour et al. [3] illustrated use of multivariate growth curve methods [6-9] to 
examine treatment arm differences in HRQL outcomes measured over time in 
SWOG9916.  This earlier analysis highlighted the presence of substantial individual 
differences in HRQL change trajectories, an important finding given the usual focus on 
average effects.  In addition, the longitudinal analysis described how relationships
between HRQL outcomes can differ as a function of treatment.  The current paper 
focuses on detailed explication of causal effects at a single time point (adjusted for 
baseline levels) rather than on descriptive longitudinal summaries.  
4Methods
SWOG9916  [4, 5]
Trial design.  Both regimens, docetaxel + estramustine (D+E) and mitoxantrone plus 
prednisone (M+P), were known to palliate pain in hormone refractory metastatic 
prostate cancer [10, 11].  In S9916, the D+E arm was hypothesized to have greater 
clinical efficacy as well as equivalent or better palliation of disease-related symptoms.  
Men with stage D1 or D2 prostate cancer were randomized to D+E or M+P; therapeutic 
results were reported by Petrylak et al. in 2004 [4] and additional detail regarding the 
therapeutic design can be found in this manuscript.  Statistically significant 
differences favored D+E for median overall survival and time to progression as well as 
for the proportion of patients with at least a 50% decrease in prostate specific antigen 
(PSA).  More grade 3/4 toxicities were observed in the D+E arm (neutropenic fevers, 
nausea and vomiting, and cardiovascular events).    
     For this illustrative application, we designate the M+P arm as “Standard or 
Control” (coded 0) and the D+E arm as “Experimental Treatment” (coded 1).  At pre-
randomization, patients were evaluated on the SWOG Performance Status (PS) 
Grading Scale. For this re-analysis of the S9916 HRQL data, we designate patients 
who were “fully or somewhat active” with a binary code of 0 (PS codes of 0 or 1), and 
those patients who were “relatively inactive” with a binary code of 1 (PS codes of 2 or 
3); this direction maintains consistency with the SWOG scoring and the categorization 
matches the PS stratification variable for the therapeutic trial [4].  The S9916 trial 
enrolled 674 patients eligible for analysis in the original reports; 629 patients had 
HRQL data.  
5HRQL assessment.  HRQL was assessed with the McGill Pain Questionnaire (MPQ) [12] 
and the European Organization for Research and Treatment of Cancer (EORTC)
Quality of Life Questionnaire – Core 30 (QLQ-C30) [13, 14] with its prostate module, 
the PR-25 [15]. The Present Pain Intensity (PPI) item from the MPQ and the GHRQL 
item from the QLQ-C30 were the two pre-designated primary HRQL outcomes for the 
trial.  To facilitate interpretation, both outcomes were scaled from 0 (best possible 
score) to 100 (worst possible score).   
For this application, we analyze the pain and GHRQL outcomes, and the 
relationship between them, at Week 10.  Six months (Cycle 8) was the pre-specified 
primary time point for the primary analyses.  However, we observed substantial 
missing data at the later time points (6 months: 56% for the EORTC QLQ-C30, 58% 
for the McGill Pain Questionnaire; 12 months: 49% for the EORTC QLQ-C30, 48% for 
the McGill Pain Questionnaire).  Therefore, this application examines pain and GHRQL 
at week 10 (Cycle 4) (adjusted for baseline levels),when both questionnaires were 
completed and submission rates were acceptable (82% EORTC QLQ-C30; 89% McGill 
Pain Questionnaire) [5].  The D+E arm had better submission rates than the M+P arm, 
consistent with the D+E arm’s statistically longer survival.  Patients who submitted 
fewer forms over time had worse scores at baseline and worsening HRQL at time of 
drop-out.  A series of pattern mixture models suggested no consistent statistically 
significant differences in global HRQL or pain by treatment arm [5].  
Statistical methods
We illustrate application of DYNAMO principles using pain and GHRQL data from the 
clinical trial described above.  In this population, pain is a prominent symptom and we 
start from the premise that pain is a critical contributor to GHRQL; if severe enough, 
6pain is almost certain to depress one’s GHRQL.  The regression of GHRQL on pain is 
thus an index of the centrality or impact of pain on the more general HRQL rating.  A
causal interpretation is also defensible:  increases in pain should cause poorer GHRQL
because pain is a constituent of GHRQL.  The converse, however, is not necessarily 
true; many aspects of GHRQL may worsen without affecting pain.  On either 
interpretation, it is reasonable to inquire whether the randomized intervention led to a 
change in the degree of association between pain and GHRQL, as indexed by the 
regression of GHRQL on pain.  
     Consistent with our emphasis on model conceptualization, the key results appear 
in Figure 1, in a manner designed to resemble the generic model of Figure 5 in 
Donaldson et al. (this issue). Omitted from Figure 1 are coefficients corresponding to 
standard baseline adjustments that regress later versions of the measured variables 
on their baseline counterparts1.  All coefficients in Figure 1 attained statistical 
significance (p < .05) using robust standard errors [16].  Figure 1 contains the key 
findings illustrating the approach, but complete syntax and technical estimation 
results using the MPlus multilevel structural equation modeling program [16] are 
available upon request.  
Results
We first summarize the major results of Figure 1, then provide additional 
interpretation guided by the four steps recommended in the companion DNYAMO 
paper (Donaldson et al., this issue).
                                                
1 These standard adjustments have no effect on the interpretation of the key features of the model, but merely 
condition responses on baseline values.  
7The direct causal effects of treatment
The Direct Causal Effect (DCE) of the intervention on Pain (Z) was not significantly 
different from zero (p=.964, likelihood ratio test), and therefore coefficient a was set to 
zero in the model and in Figure 1.  This, by definition, defined the mediating path X-
>Z->Y as zero. The DCE on the relational outcome (corresponding to b in Figure 5 
from the companion paper) was important, however.  The coefficient of .20 combines 
additively with the intercept coefficient of .17 to signify that the effect of Pain on 
GHRQL is roughly twice as strong in the D+E group as in the M+P group.  For D+E, a 
unit worsening of 1 Pain point led, on average, to a .37 (.17 + .20) worsening of 
GHRQL, compared with a .17 value for M+P.  To put it in a more realistic context, a 
50-point increase on a 0 to 100 pain scale would lead, on average, to an 18.5-point 
worsening in GHRQL in D+E, but only an 8.5-point worsening in M+P.  This is the 
causal reading of the coefficients.  An alternative interpretation is that the intervention 
led to a less central role for pain in evaluating GHRQL in the M+P group.  The DCE of 
treatment on GHRQL (Y, the designated endpoint), was moderated by pre-
randomization Performance Status.  The D+E treatment intervention directly caused 
an average improvement of 5.89 GHRQL points in the good performance status 
stratum (PS=0), but only a negligible improvement of .25 GHRQL points in the poor 
performance status stratum (PS=1).  
Treatment effect mediation
In this study there was no direct effect of therapy on the mediator Pain, and hence no 
Average Mediating Effect on GHRQL via Pain.   There are nonetheless nonzero and 
differing Individual Mediating Effects, because patients in both arms differ in their 
mediating pain scores.  Patients with pain scores Zi that lie far from the average (who 
8have extreme values of UZ) would experience greater mediation than patients with pain 
scores near the average, since 1 0( ) ZiIME U   even when the means of Z are equal 
(see Table 1 in the companion paper).    
Average causal effect
Because there was no Average Mediated Effect (since the DCE of treatment on Pain 
was zero), the Average Causal Effect (ACE) within each performance stratum equals 
the DCE within that stratum.  Although it is possible to calculate an overall ACE
across performance strata, the number does not represent the expected causal effect 
for patients in either stratum.  
What made GHRQL happen in one randomized controlled trial?  A second look
The strategies and guidelines suggested in the companion paper provide an approach 
to more comprehensive analysis of the full spectrum of causes and responses 
operating during a clinical trial.
1.  Examine and report the diversity of individual responses, treated separately from 
“error.” 
Significant individual differences, systematic and distinct from random error, 
modulated the relational outcome.  The random regression of GHRQL on Pain had a 
variance estimate of .024.  This variance appears small in absolute terms, but 
converting to the standard deviation scale helps place it in proper context.  The 
corresponding standard deviation of .15 is nearly as large as the .20 average difference 
in slopes between treatment arms, hence there is considerable individual variability in 
the strength of association between Pain and GHRQL in this population.  The 
regression coefficients for two randomly selected patients from the same treatment 
9arm would be expected to differ by .21 (.15 x square root of 2), which exceeds the 
expected average difference between arms.  Figure 2 represents the range of individual 
relational outcomes relative to treatment arm average differences.  Each individual’s 
relational outcome is a personal attribute indicating a dispositional sensitivity to pain, 
conceptually distinct, and estimated separately, from “error.”  More complex 
longitudinal designs would permit full characterization of modulators generating 
individual differences in direct causal effects on the Pain and GHRQL outcomes as well 
as on the relational outcome.
2.  Evaluate whether treatment has affected the relationships as well as the levels of 
outcome variables.  
In this trial there were two important DCEs that operated separately.  The intervention 
(D+E instead of M+P) tended to improve the level of GHRQL in one performance 
stratum but also to increase the sensitivity of GHRQL to pain in both strata.  Both 
causal aspects are crucial to understanding whether patients receive benefit from an 
intervention.  Increased sensitivity to Pain leads to increased volatility in GHRQL, a 
negative result that may be offset by direct improvement in GHRQL.  In Step 4, we 
illustrate how questions of benefit depend on the details of patient mediation, 
moderation, and modulation.  
3.  Include and evaluate moderators of the treatment intervention. 
The DCE of treatment depended on the level of the pre-randomization Performance 
Status measure.  The benefit of understanding moderated interventions is great, 
because it allows prediction of who will benefit from therapy.  In our substantive 
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example, patients with poor performance status tend to receive little benefit from the 
D+E treatment beyond that offered by M+P.  
4.  Consider individual causal inference.  Evaluate the extent to which the treatment 
was responsible for the observed changes in individual patients.
Although a full presentation of these procedures is beyond this paper’s scope, we 
would like to introduce the expanded inference possible under a comprehensive causal 
model like DYNAMO.  The key idea involves estimating the Individual Causal Effects
(ICEs) for each patient on the trial, and combining this information with observed 
change to deduce what role the therapy must have had in effecting change.  
     Because causal models are modular, it is meaningful to ask what would happen to 
Y if we could intervene to change the treatment a patient received while holding 
constant that patient’s other causes of Y, Z, and .  This is the ICE.  Under the
modularity assumption, the remaining (non-treatment) causes of Y can be directly 
calculated, once the ICE is estimated from the model (since Y is known, as suggested 
in Figure 3).  Holding background variables constant, one can compare the estimated 
ICE with the observed change and deduce whether change in Y happened because of, 
despite, or regardless of the intervention [17].  Table 1 presents this process for three 
representative patients from the SWOG trial.  The first data column presents the 
estimated ICE from the model (reflected in the “good” direction, for ease of 
interpretation), while the second data column contains the adjusted gain in GHRQL 
from baseline (also reflected in the “good” direction).  The third column then computes 
the value for Uy, the sum of other causes, by subtraction.  Conditional on the modular 
causal assumptions of Figure 3, the final column, labeled Y*, calculates the 
(counterfactual) value expected for GHRQL if we could intervene to set the patient’s 
11
ICE to zero (receiving no benefit from treatment).  Y* is the expectation for what would 
have happened to Y had the ICE been zero instead of what it really was.
     Figure 4 portrays these results on a coordinate scheme cross-classifying observed 
change and ICEs.  All three patients were observed to improve (positive change) on 
GHRQL, and hence are plotted above the abscissa.  We now consider why the patients 
improved.  Patient A experienced an ICE of +10 from therapy, but had this effect been 
zero, A would have worsened by 5 points instead, since other causes were negative.  
Therapy was thus necessary for A’s improvement; legal and common language 
reasoning describe A as improving because of therapy, since A would not have 
improved otherwise.  Now consider Patient B, who had an ICE of +5 and was observed 
to improve by 17.  Had B’s ICE been zero, B would still have improved (though by +12 
instead of +17); we say B improved regardless of therapy, since other causes would 
still allow B to experience a positive change.  Finally, consider Patient C, who 
improved despite having a negative (harmful) causal effect of therapy.  Had C not 
received therapy, C would have improved by 19 points instead of only 7.  
     As the geometry of Figure 4 makes clear, any patient falling into the same sector as A, 
B, or C shares the respective causal attribution for that sector.  Patients observed to 
worsen instead of improve fall into sectors below the abscissa having corresponding, 
though reversed, interpretations.
     Figure 5 represents a comprehensive cross-classification for all patients on the trial 
in the manner of Figure 4 for both M+P (left panel) and D+E (right panel).  Each point 
in the causal attribution plots represents an observed HRQL change and an inferred 
(estimated from the model) ICE.  The side-by-side comparison is telling.  Only one 
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patient in the M+P group improved because of therapy2, while 15 patients in the D+E 
arm improved because of therapy.  Three D+E patients worsened because of therapy, 
but over 25 M+P patients worsened because of therapy.  The bivariate distributions of 
Figure 5 present compelling as well as innovative evidence supporting the general 
efficacy of the D+E intervention.  At the same time, the comprehensive cross-
classifications identify the smaller number of patients who benefited from the M+P 
therapy, as well as some of their characteristics.  (In this analysis, those benefiting 
from M+P were primarily low performance status patients having extreme pain who 
would receive large mediating effects from M+P’s advantage in the relational outcome
but who would not receive the benefit of D+E’s direct causal effect on GHRQL, which 
operated only within the high performance stratum.)  Almost as many patients 
improved on M+P as on D+E.  However, reasons for improvement differed.  D+E 
patients improved in large part because of treatment whereas M+P patients improved 
despite or regardless of treatment.  Therefore, other causes are at least as important 
as treatment in explaining why GHRQL changes happen.  
     In more definitive analyses, one could incorporate standard errors of estimation 
and pragmatic effect sizes to allow regions of uncertainty as well as practical 
importance.  The simplified example presented here collapses all other causes of Y into 
a single category.  This is mathematically accurate, but unsatisfactory in that the set 
of all other causes subsumes random measurement error.  In longitudinal analyses, it 
would be possible, and highly desirable, to distinguish systematic causes of individual 
differences from random measurement error.  
                                                
2 In this and all statements drawn from Figures 3 and 4, the conclusions about therapeutic impact pertain to receiving 
one therapy instead of the other.  The attributed causal impacts are relative, not absolute.  
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Discussion
A “standard” analysis of SWOG9916 would indicate that, adjusted for baseline 
GHRQL, the D+E Cycle 4 GHRQL mean was 3.35 points lower than the M+P mean, a 
difference that does not quite reach statistical significance (p=.078), in line with the 
nonsignificant GHRQL results reported in the primary publication [5].  According to 
traditional guidelines, the “treatment did not work” better than the comparator for 
GHRQL.  Yet this summary conclusion is both inaccurate and incomplete.  In fact the 
study provides an interesting combination of findings, leading to a more nuanced 
interpretation of treatment effects.  Consider first the moderated intervention.  
Whether the treatment “works” depends on which kind of patient you are.   For good
performance status patients, D+E had a beneficial Direct Causal Effect (DCE) on 
GHRQL, improving it on average relative to the M+P group.  Since the average 
mediated effect was zero, the DCE is equivalent to the Average Causal Effect (ACE):  
the D+E treatment appeared to work, on the average, for patients with good
performance status.  For the poor performance stratum, the DCE, and hence the ACE, 
were negligible.  
     Several familiar statistical approaches can work well to evaluate moderators, and 
one need not rely on the full DYNAMO framework to address the critical question of 
differential treatment benefit.  Conventional moderated regression (i.e., incorporation 
of an interaction term or the conduct of separate subgroup analyses) [18] or a two-
group structural equation approach [1, 9, 16] would yield similar conclusions for the 
moderating effect of performance status.  The difficulties with evaluating moderators 
are less technical than substantive and psychological:  one must know what to 
measure and maintain a certain equanimity in the face of complexity.  With moderated 
interventions, randomized controlled trials cannot yield a single answer to how well a 
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treatment works.  This reality resides in the diversity of individual attributes, not in 
the statistics.   An important prerequisite is to understand the clinical mechanisms, 
which in turn suggest which moderators to measure.  These may then be included in 
statistical models such as the DYNAMO approach proposed here to provide important 
insights into improved clinical management.  
     In the SWOG trial, understanding benefit depends on reconciling causal effects 
that may not work in tandem.  The D+E arm provided an average direct benefit to 
patients with good performance status, but not with poor performance status 
(moderated intervention).  Yet D+E also led to greater sensitivity of GHRQL to Pain 
than did M+P (relational outcome).  These two interactions, the relational outcome and 
the moderated intervention, are to a considerable extent in opposition, with 
conclusions depending on particular combinations of values for Pain and GHRQL.  
Although common statistical practice sanctions transforming variables to eliminate 
interactions, this may be counterproductive when these interactions are themselves of 
primary clinical interest.  Taking interactions seriously requires that the metrics of 
clinically interacting variables be treated somewhat consistently across studies.  
     Standard approaches to the mediation problem [18-20] assume that a nonzero 
association between X and Z is a necessary condition for Z to mediate the effect of X 
on Y.   Though this assumption seems reasonable, it may inappropriately rule out 
many interesting patterns of mediational results [21-24].  In S9916, the DCE of X on Z 
was zero, and hence the Average Mediating Effect of X on Y via Z was zero.   
Traditional methods, such as those expressed in Baron and Kenny’s [18] regression 
rules, take this finding as evidence that Z is “not a mediator.”  The Individual 
Mediating Effects (modulation), however, are not zero.  Consider a Control patient with 
a Pain score one standard deviation, about 23 points, above the Control mean.  The 
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Individual Mediating Effect for that patient is an expected improvement of 23(1 - 0) = 
23(.20) = 4.6 HRQL points by virtue of the treatment change in the relational outcome.  
A full range of Individual Mediating (and hence causal) Effects may arise even when 
the population average relationship is zero.  By any method, the relational outcomes 
in the SWOG trial differ between treatment arms.  Ordinary least squares regression 
with observed variables including an interaction term yields results that agree with the 
DYNAMO average relational outcomes, estimating  the treatment arm regression 
coefficients as .37 and .17 for D+E and M+P, respectively (see also [3]).  
     The relational outcome captures a unique aspect of the treatment’s effect.  
Independent of performance status, the intervention led to a reduced average impact 
of – a less central role for – pain in the M+P group.  Important individual differences 
modulated the relational outcome, however.  Figure 2 presents boxplots showing the 
relational outcome distributions separately by treatment arm.  The boxplots indicate 
that the modulation by individual differences (the spread or length of the boxplots) is 
at least as important as the direct causal effect of the intervention (the distance 
between the median values).   The dependence of GHRQL on pain varied widely across 
patients within each treatment arm, using model-based estimates that are 
theoretically purged of measurement error.  Nonetheless the direct causal effect of the 
intervention was substantial:  roughly speaking, the 25th percentile of the D+E arm 
corresponds to the 75th percentile of the M+P arm.   The treatment effect on the 
relational outcome may reflect the anti-inflammatory role of the prednisone 
component of the M+P combination [5].  The presence of prednisone may reduce the 
functional consequences of inflammatory pain, even though the direct causal effects of 
therapy on pain were equivalent.  That is, for the same degree of pain, we speculate 
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that the extent of mobility and activity possible could be greater in the M+P arm, over 
against the direct benefit of D+E (in the good PS stratum) on GHRQL.  
     If this interpretation is correct, it presents an interesting example of the clinical 
tradeoffs that can be considered using the DYNAMO approach.  In patients for whom 
severe pain is the primary risk to quality of life, the M+P arm might be the better 
choice when weighing the risks and benefits of treatment (recalling that there was a 
therapeutic benefit for D+E) regarding HRQL.  In high performance patients with less 
severe pain, but with broader-based GHRQL limitations, the D+E therapy would 
generally be superior.  
     A key objective of this analysis has been to express the conditional dependence of 
the Z->Y relationship on X.  It is of course completely equivalent statistically to 
express the conditional dependence of X->Y on Z.  Or, in many situations, one may 
only wish to consider the relational outcome with respect to the symmetrical 
association of Y and Z, and consider this covariance as the outcome.  Rather than the 
directed graph motivating the present analyses, one could as well consider graphical 
models, such as chain graphs, interaction graphs, and conditional Gaussian graphs, 
that are at least partly undirected [25]. In fact, we have conducted all these 
approaches using the general graphical modeling program MIM [26], and these have 
led to similar statistical conclusions.  
     Still, we believe there are advantages for the directed approach when justifiable.  It 
provides a natural interpretation for the real and hypothetical experiments about what 
would happen if variables were manipulated in a certain sequence.  A secondary 
consideration is that a fully directed model permits random effect components that 
correspond naturally to individual differences.  
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Table 1  Causal attributions for individual patients
Patient ICE Y (GHRQL) Uy= Y - ICE Y* 
= | 0Y ICE 
= UY
A 10 5 -5 -5
B 5 17 12 12
C -12 7                       19                    19
19
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Figure Legends
Figure 1.  Key results of the relational outcome model applied to the SWOG 9916 
example.  The Direct Cause Effect (DCE) of Treatment (TX, 0=M+P, 1=D+E) on Pain was 
zero, so the Average Mediated Effect was also zero.  The DCE of Treatment on the 
relational outcome  showed that the average dependence of GHRQL on Pain was 
roughly twice as strong in the D+E arm (.17+.20) as in the M+P arm (.17).  The i values 
varied across patients, with within-group variance equal to .024 (SD=.15).  The DCE 
of treatment depended on the level of the pre-randomization Performance Status measure.  
The randomized treatment intervention caused an average improvement of 5.89 GHRQL 
points in the good performance status stratum, but only an improvement of .25 GHRQL 
points in the poor performance status stratum.  Since the Average Mediated Effect was 
zero, the Average Causal Effects equaled the Direct Causal Effects (5.89 GHRQL 
improvement for PS=0, .25 GHRQL improvement for PS=1).
Figure 2.  Boxplots of the distributions of the relational outcome slope coefficient for 
individuals in the M+P and D+E treatment arms.  The relational outcome is an 
individual’s expected change in GHRQL given a one-unit increase in Pain, 
E(GHRQL|Patient=i,Pain=p+1) – E(GHRQL|Patient=i,Pain=p), if other variables could 
be held at fixed values.  This is a systematic attribute of a person, distinct from 
measurement error.  The boxes show the 75th and 25th percentiles, with the central 
lines denoting the medians.  The whiskers include the non-outlying values, while the 
isolated dots represent outliers.  The interquartile range (75th percentile – 25th
percentile) was approximately equal to the average treatment arm difference, so both 
population and individual relational effects were important.
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Figure 3.  Partitioned causes of observed GHRQL change in individual patients.  
Causal models are modular, representing the expected changes from controlled 
manipulations holding constant other variables.  The Individual Causal Effect (ICE)
 summarizes relationships in Figure 1 to show how GHRQL (Y) would change for a 
particular patient because of treatment (if he or she were to receive the other 
randomized intervention, holding constant all other causes).  Under these 
assumptions of modularity and unchanged other causes, the total cause of Y must 
equal the sum of a patient’s ICE and all other causes UY.  Therefore one can calculate 
UY by simple subtraction once the ICE has been estimated.  
Figure 4.  Model-based estimation and counterfactual inference for individual patients.  
The abscissa in this scatterplot represents the model-based Individual Causal Effect (ICE) 
estimate, while the ordinate is the observed Y (GHRQL) adjusted for baseline (a residual 
“change” score).  Patients A and B had both positive (beneficial) causal effects from therapy 
and positive (beneficial) observed change in Y.  Patient A had an estimated positive 
ICE of 10, but an observed improvement of only 5, hence the other causes of Y amounted 
to -5.  Holding constant the other causes, the value expected for Y if the ICE were 
modified to zero would be -5.  Hence A’s improvement would not have happened without 
therapy:  A improved because of therapy.  Patient B’s observed improvement was 17, 
of which only 5 resulted from therapy.  If the ICE had been zero for B, we still would 
have observed a positive change of 12 for B; hence B improved regardless of therapy.  
Patient C had a negative (harmful) ICE of -12, but a positive observed change of 7.  
Thus C improved despite therapy; C would have improved by even more without the 
harmful effect of therapy.  Any patient falling in the same sector as patients A, B, or C 
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shares the causal attribution appropriate for that sector.  The causal attributions for 
patients who worsen (below the abscissa) follow similarly.
Figure 5.  Causal attribution plots for the M+P (left panel) and D+E (right panel) 
treatment arms.  The plots contain the specific model-based and observed data points 
for all patients.  The sectors of the plots correspond to the definitions in Figure 4.  For 
example, the upper left quadrants of both panels contain data for patients who 
improved despite therapy.  The lines of identity are not represented diagonally in these 
plots because the ranges are greater for observed data (the ordinates) than for the 
Individual Causal Effects (ICEs) (the abscissas); this is a graphical display choice 
made to enhance point visibility and has no effect on the interpretations, which are 
identical to those of Figure 4. 
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